Genomma Lab Internacional SAB de CV

In the wake of what can only be described as an extraordinary year, Generics Bulletin’s annual ranking of the world’s top 50 generics and biosimilars companies has seen major disruption, as companies

Mexico’s Genomma Lab Internacional SAB de CV reported OTC sales up by 32.2% to MXN1.96bn ($86.9m) in the second quarter of 2020 as turnover advanced significantly two of its three reporting regions.

Genomma Gets Gains Across Board Mexico’s Genomma Lab Internacional SAB de CV reported OTC sales up by 7.5% to MXN1.48bn ($75.4m) in the second quarter, as turnover improved at single-digit rates in

Genomma Enjoys Broad-Based Growth Mexico’s Genomma Lab Internacional SAB de CV reported OTC sales up by 14.2% to MXN6.07bn ($314m) in 2018, as turnover improved at a double-digit rate in all three of